Novartis ends mid-stage trial for Fabhalta in lupus nephritis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| NOVARTIS AG (NYSE: NVS) | Delayed: 156.27 +2.34 (1.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $153.93 | 52 Week High | $89.15 | |||
| Open | $154.90 | 52 Week Low | $69.84 | |||
| Day High | $157.10 | P/E | N/A | |||
| Day Low | $154.38 | EPS | $0.00 | |||
| Volume | 2,081,350 | |||||
